Welcome to our dedicated page for Red Light Hollan news (Ticker: TRUFF), a resource for investors and traders seeking the latest updates and insights on Red Light Hollan stock.
Red Light Holland Corp. reports developments in legal regulated botanical wellness, natural-product therapeutic research, and regulated consumer products. The Ontario-based company owns Filament Health Corp., a clinical-stage natural botanical therapeutics developer with GMP production capabilities, FDA regulatory engagement, a global clinical research footprint, and PEX010, a patented botanical research compound therapeutic candidate.
Company news commonly covers peer-reviewed clinical data, research-institution distribution of PEX010, exclusive licenses to trial data and related intellectual property, and R&D initiatives based on consensual data collection. Updates also address commercial activities in Europe and North America, including regulated consumer product sales in the Netherlands' legal market and home cultivation kits sold through B2B and direct-to-consumer channels.
Red Light Holland (OTCQB:TRUFF) reported that joint venture partner Magdalena Biosciences achieved positive preclinical results with a whole-leaf coca extract, its prescription drug candidate for post-GLP-1 weight loss management.
In a 20-day mouse study on a high-fat diet, the extract prevented weight gain without reducing food intake or increasing activity, supporting further development under FDA Botanical Guidance.
Red Light Holland (OTCQB:TRUFF), through wholly owned subsidiary Filament Health, signed an agreement with GHU Paris Psychiatrie & Neurosciences to supply its patented botanical psilocybin drug candidate PEX010 for the KETAPSYCHECOG academic study in France.
The randomized, double-blind, cross-over trial in healthy volunteers compares behavioral and neural effects of psilocybin and ketamine. The deal expands Filament’s clinical research footprint to France. PEX010 is already supplied to 80+ regulated studies worldwide.
Red Light Holland (OTCQB:TRUFF) announced that Filament Health’s standardized, patented natural psilocybin drug candidate PEX010 was selected by UCSF for a double-blind, randomized trial in healthy older adults with low well-being.
The study will assess safety, feasibility and effects on brain activity, neuroinflammatory biomarkers, and preclinical Alzheimer’s disease markers. PEX010, trusted in 80+ studies worldwide, is produced with proprietary extraction and stabilization methods. Red Light recently closed its acquisition of Filament, adding 76 issued patents across 15 families and PEX010 to its portfolio.
Red Light Holland (OTCQB: TRUFF) signed an addendum with Allu Therapeutics, expanding their New Zealand supply agreement to include Filament Health's GMP-compliant PEX010 botanical psilocybin drug candidate.
The deal adds Filament as a supplying affiliate and introduces a standardized microdose format of PEX010, already used at 70+ clinical research sites worldwide.
Red Light Holland (OTCQB: TRUFF) reported new clinical activity for its wholly owned subsidiary Filament Health’s botanical psilocybin candidate PEX010 following Filament’s acquisition.
PEX010 shipments now support Canadian academic studies in palliative care (Phase I/II and planned Phase 3), bipolar II treatment-resistant depression, and healthy adult mechanism research, while backing over 70 research studies worldwide and a 76‑patent portfolio.
Red Light Holland (CSE: TRIP, OTCQB: TRUFF) shareholders overwhelmingly approved a proposed corporate name change at the May 11, 2026 annual general and special meeting. Shareholders also approved auditor re-appointment, a share consolidation, and elected all nominated directors. The company announced CFO Keith Li's planned resignation and settled $735,874.22 of debt via issuing 18,396,855 common shares at $0.04 per share.
Red Light Holland (OTCQB: TRUFF) highlighted a JAMA Network Open randomized trial (published May 7, 2026) reporting a single synthetic dose of psilocybin reduced cocaine use versus active placebo through six months.
Filament Health holds an exclusive worldwide license to the trial data/IP and has Phase 2 authorization from the FDA and Health Canada for its botanical candidate PEX010.
Red Light Holland (OTCQB: TRUFF) confirmed expanded distribution of Filament Health's botanical psilocybin drug candidate PEX010 across Canadian and U.S. research institutions and compassionate use patients.
Highlights include repeat shipments to University of Calgary and UCSF, a first-time Canadian academic shipment, multiple compassionate-use deliveries, third-party lab testing support, and completion of Red Light's April 30, 2026 acquisition of Filament with 76 issued patents.
Red Light Holland (OTCQB: TRUFF) announced an intended corporate rebrand following the closing of the Filament Health acquisition and said a new name will be proposed at the Annual General and Special Meeting on May 11, 2026.
The combined company adds GMP manufacturing, FDA-aligned drug development capabilities and a lead botanical psilocybin candidate, PEX010, currently evaluated at >70 clinical research sites. Management urged shareholders to vote IN FAVOUR of the name-change resolution; details will be in the management information circular.
Red Light Holland (OTCQB: TRUFF) completed its acquisition of Filament Health effective April 29, 2026, creating a vertically integrated psychedelic platform combining Filament's pharmaceutical-grade R&D, a Health Canada Dealer's License, and a portfolio of 70+ patents with Red Light's global distribution.
The transaction issued 99,180,497 consideration shares plus 70,836,683 shares for debt settlement, leaving 595,727,901 Red Light shares outstanding and former Filament holders owning approximately 30%.